Zobrazeno 1 - 10
of 52 726
pro vyhledávání: ''
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:1945-1961
Background: Chalcone is a broad-spectrum natural product with anti-cancer and anti-inflammatory activities. However, low potency, low selectivity, and serious side effects limit its druggability. L-Tryptophan is an essential precursor molecule of an
Autor:
Joanna Parkinson, David W. Boulton, Weifeng Tang, Robert C. Penland, Bengt Hamrén, Melin J, Dinko Rekić
Publikováno v:
The Journal of Clinical Pharmacology. 62:1227-1235
Aim: Dapagliflozin improves glycaemic control in patients with type 2 diabetes mellitus (T2DM) and is approved in European and Japanese patients with type 1 diabetes mellitus (T1DM) with inadequate glycaemic control. The objectives of this work were
Autor:
Lin Wang, Jiuwei Chen
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:579-585
Background: Cervical intraepithelial neoplasia (CIN) directly precedes cervical cancer, and elevated proinflammatory cytokine interleukins (IL)-6 is implicated in CIN. Objective: As maslinic acid exhibits anti-IL-6 property, the present study sought
Autor:
Helen Carnaghan, Joanne Bal, Rab K. Prinjha, Jackie C. Bloomer, Jack A. Brown, Peter Ernest Soden, Palwinder K. Mander, Sarah J Hopkins, João Joaquim Oliveira, Lars Erwig, William A. Fahy, Yi Cui, Shruti Daga, Bill Davis, Monica Simeoni, Disala Fernando, Peter Williams, Gabriel K. Wong, Edward Banham-Hall
Publikováno v:
British Journal of Clinical Pharmacology. 88:2140-2155
GSK3358699 is a mononuclear myeloid-targeted bromodomain and extra-terminal domain (BET) family inhibitor which demonstrates immunomodulatory effects in vitro. This phase 1, randomized, first-in-human study evaluated the safety, pharmacokinetics, and
Publikováno v:
Exp Clin Psychopharmacol
Protein kinase C (PKC) is important for the mechanism of action of amphetamine (AMPH). Inhibiting PKC blocks AMPH-stimulated increases in extracellular dopamine levels and AMPH-stimulated locomotor activity. This study examined the effects of PKC inh
Autor:
Philippe Ruszniewski, Tahir Shah, Ulrich Frank Pape, Aude Houchard, Marianne Pavel, C. Lombard-Bohas, Xuan-Mai Truong Thanh, Francesco Panzuto, Ivan Borbath, Jarosław B. Ćwikła, Jaume Capdevila
Publikováno v:
Scientia
European journal of cancer (Oxford, England : 1990), Vol. 157, no.157, p. 403-414 (2021)
European journal of cancer (Oxford, England : 1990), Vol. 157, no.157, p. 403-414 (2021)
Lanreotide; Progression-free survival; Somatostatin Lanreótido; Supervivencia libre de progresión; Somatostatina Lanreòtid; Supervivència lliure de progressió; Somatostatina Introduction This prospective, single-arm, phase 2 study assessed the e
Autor:
Ying Han, Xingxing Wang, Xuanxuan Liu, Li Zhao, Shuo Sun, Haiyang Tang, Changlei Bao, Ang Luo, Yan Pan
Publikováno v:
Drug Design, Development and Therapy
Purpose Endothelial dysfunction and the subsequent decrease in endothelium-dependent vascular relaxation of small arteries are major features of hypertension. Artemisinin, a well-known antimalarial drug, has been shown to exert protecting roles again
Autor:
Nathaniel F. Watson, Jeffrey M Dayno, Ben Vaughn, Donna Zarycranski, Craig W. Davis, Yves Dauvilliers, Jean-Charles Schwartz
Publikováno v:
CNS Drugs
Background Pitolisant is approved in the USA and Europe for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. Objective Analyses evaluated the time to onset of clinical response during treatment with pitolisant. Me
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 130:56-69
Oleandrigenin-3-O-β-D-diginoside (a derivative of odoroside A), isolated and purified by our group, has seldom been explored for its pharmacological activity. This study aimed at clarifying the mechanisms towards the leukaemia-suppressive role of od